A Model‐Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive Dyskinesia

Ähnliche Einträge

• Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham
  von: Ryan L. Crass, et al.
  Veröffentlicht: (2024)
• Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years
  von: Sachiko Mita, et al.
  Veröffentlicht: (2025)
• Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis
  von: Thomas Dumortier, et al.
  Veröffentlicht: (2025)
• Model‐Informed Drug Development Supports Full Approval of Ibuprofen Injection in Chinese Pediatric Patients With Fever or Pain
  von: Qianxi Lou, et al.
  Veröffentlicht: (2025)
• Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
  von: Mohamed A. Kamal, et al.
  Veröffentlicht: (2024)